Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. In today’s report we highlight attractive Groups and stocks within Health Care: Biotech, Large-Cap, Biotech, Mid-Cap, Hospitals, and Rehab Services.</p>

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. In today’s report we highlight attractive Groups and stocks within Health Care: Biotech, Large-Cap, Biotech, Mid-Cap, Hospitals, and Rehab Services.

U.S. Equity Strategy: Upgrading Health Care to Overweight

<p>The S&amp;P 500 is beginning to come off of short-term overbought extremes, consolidating near the confluence of key overhead resistance and the 200-day moving average. This level is roughly 2,817 on the S&amp;P 500 and roughly 1,000 on the S&amp;P 600 Small Cap index. Some consolidation or a mild pullback is possible in the near-term, which we believe would help alleviate current overbought readings and allow for a more orderly and meaningful move higher.  In today’s report we highlight attractive Groups and stocks within the Consumer Discretionary, Health Care, and Services Sectors.</p>

The S&amp;P 500 is beginning to come off of short-term overbought extremes, consolidating near the confluence of key overhead resistance and the 200-day moving average. This level is roughly 2,817 on the S&amp;P 500 and roughly 1,000 on the S&amp;P 600 Small Cap index. Some consolidation or a mild pullback is possible in the near-term, which we believe would help alleviate current overbought readings and allow for a more orderly and meaningful move higher.  In today’s report we highlight attractive Groups and stocks within the Consumer Discretionary, Health Care, and Services Sectors.

S&P 500 and S&P 600 Testing Resistance...Still

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Bio-Techne Corporation recently shared their financial outcomes for the fourth quarter and the fiscal year 2025.</li><li>The company reported a solid quarter, with a 3% organic revenue growth driven mainly by the biopharma end markets, particularly among large pharmaceutical clients.</li><li>This growth was attributed to the company's products, such as automated proteomic analytical instruments and cell therapy solutions.</li></ul>

Bio-Techne Corporation recently shared their financial outcomes for the fourth quarter and the fiscal year 2025.The company reported a solid quarter, with a 3% organic revenue growth driven mainly by the biopharma end markets, particularly among large pharmaceutical clients.This growth was attributed to the company's products, such as automated proteomic analytical instruments and cell therapy solutions.

Bio-Techne Faces NIH & Tariff Uncertainty–Can They Outpace Policy Risks?

<ul><li>Bio-Techne reported its third-quarter fiscal year 2025 results, exhibiting a strong performance despite navigating a challenging macroeconomic environment.</li><li>The company achieved 6% organic revenue growth, underscoring its resilience in the face of various uncertainties and highlighting the importance of its diversified product portfolio, including core reagents, automated analytical solutions, and cell and gene therapy offerings.</li><li>This growth was achieved while maintaining a robust adjusted operating margin of 34.9%, facilitated by strategic investments in operational efficiencies.</li></ul>

Bio-Techne reported its third-quarter fiscal year 2025 results, exhibiting a strong performance despite navigating a challenging macroeconomic environment.The company achieved 6% organic revenue growth, underscoring its resilience in the face of various uncertainties and highlighting the importance of its diversified product portfolio, including core reagents, automated analytical solutions, and cell and gene therapy offerings.This growth was achieved while maintaining a robust adjusted operating margin of 34.9%, facilitated by strategic investments in operational efficiencies.

Bio-Techne Corporation: An Insight Into The Pharmaceutical Market Dynamics & China's Economic & Regulatory Environment!

<ul><li>Bio-Techne Corporation's second quarter of fiscal year 2025 results showcased a blend of robust growth and some challenges.</li><li>The company reported a 9% year-over-year increase in revenue, achieving $297 million in total sales, which was also the growth rate on an organic basis.</li><li>This performance was largely fueled by significant contributions from the biopharma end markets, especially large pharmaceutical orders for Good Manufacturing Practice (GMP) reagents and protein analytical implementations, alongside notable strides in their ExosomeDx and spatial biology divisions.</li></ul>

Bio-Techne Corporation's second quarter of fiscal year 2025 results showcased a blend of robust growth and some challenges.The company reported a 9% year-over-year increase in revenue, achieving $297 million in total sales, which was also the growth rate on an organic basis.This performance was largely fueled by significant contributions from the biopharma end markets, especially large pharmaceutical orders for Good Manufacturing Practice (GMP) reagents and protein analytical implementations, alongside notable strides in their ExosomeDx and spatial biology divisions.

Bio-Techne Corporation: How Spatial Biology and Molecular Diagnostics Are Changing the Game!

United States

Bio-Techne Corp develops, manufactures and sells biotechnology products and clinical diagnostic controls. The Company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bio Techne Corp (TECH US)

U.S. Equity Strategy: Upgrading Health Care to Overweight

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year...

Vermilion Research

S&P 500 and S&P 600 Testing Resistance...Still

The S&P 500 is beginning to come off of short-term overbought extremes, consolidating near the confluence of key overhead resistance and the...

Vermilion Research

Bio-Techne Faces NIH & Tariff Uncertainty–Can They Outpace Policy Risks?

Bio-Techne Corporation recently shared their financial outcomes for the fourth quarter and the fiscal year 2025. The company reported a solid...

Baptista Research

Bio-Techne Corporation: An Insight Into The Pharmaceutical Market Dynamics & China's Economic & Regulatory Environment!

Bio-Techne reported its third-quarter fiscal year 2025 results, exhibiting a strong performance despite navigating a challenging macroeconomic...

Baptista Research

Bio-Techne Corporation: How Spatial Biology and Molecular Diagnostics Are Changing the Game!

Bio-Techne Corporation's second quarter of fiscal year 2025 results showcased a blend of robust growth and some challenges. The company reported a...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)